INTRODUCTION

RWE, Market Access, Pricing & Reimbursement 2024 Americas  

On a global scale, the pharmaceutical market is expected to grow in the years to come regardless of a recent slowdown in key markets across the globe. The increase is exacerbated by the growing and ageing population in key markets. Aside from this, increasing access to Pharmaceuticals to poor and middle-class families due to increases in disposable income also drives the industry’s growth. Pharma companies focusing on Rare and speciality medicines is another aspect leading the growth. Innovations attracting investments even from non-pharma companies are also sustaining the growth in the pharmaceutical industry.

The pharmaceutical industry is one of the major players in the healthcare sector. Payers want to provide access and fund innovative treatments to improve patient care but governments across the globe are struggling to balance the desire to provide timely access to innovative medicines with the need to contain healthcare spending due to the increasing pressure between the demands of the EU, US, national
governments and regional authorities.

RWE is playing an increasingly critical role in supporting every aspect of successful evidence-generation programs and presents immense possibilities, it also brings substantial challenges that continue to cast shadows on its validity. Concerns such as data viases, data quality, and the possible false results due to data mining, progress have diminished primarily.

The upcoming 2024 RWE, Market Access, Pricing and Reimbursement World Congress Americas will present a dynamic approach to key trends and insights on market access, health technology assessment, real-world data, patient access, pricing and reimbursement on the current European landscape.

This year, we are putting together an agenda that addresses “Defining Value to Obtain Informed Evidence Optimizing Patient Access to Medicines”. We are gathering together high caliber expert speakers to participate and share their knowledge and expertise through Keynote Presentations and Panel discussions, addressing all aspects of the industry.

We look forward to welcoming you to the RWE, MAPR 2024 congress!

Gain insights on:

• Take part in meaningful discussions with industry experts and key decision-makers on current trends and best practices
• Realise the potential of RWE to achieve launch success and optimal market access
• Acknowledge the importance of RWD and RWE not only to better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support.
• Learn from your peers about pricing and reimbursement systems in their market
• Know how to implement a successful market access strategy and how to communicate value to stakeholders
• Recognise the importance of innovative real-world evidence partnerships for better data
• Hear an overview of the market access system in place in large pharma markets
• Gain knowledge of the Market Access environment in Europe’s major markets
• Find out the role of emerging markets Challenges and opportunities in pricing, reimbursement and patient access
• Global and European MA trends, collaboration and spillovers
• Payer & industry perspective for better access
• Patient-centred approach for better outcome
• Recognize the regulatory and clinical development framework that made an RWE- enabled development strategy attractive
• Learn how to apply successful use cases, real-world examples, and practical outcomes into your own company or organization
• Network with like-minded professionals to deliberate on best strategies, practices and lessons learned

Who Should Attend

Network with members of the boards, VP’s, Directors, Heads/Chiefs and Senior Managers of leading biopharmaceutical and biotech companies, government, CRO and solution providers involved in:

• Real-World Evidence
• Real-World Data
• Clinical Research and Development
• Data Science, Technologies and Analytics
• Clinical Research
• Epidemiology
• Health Economics and Outcomes Research
• Market Access
• Reimbursement
• Patient Outcomes
• Drug Pricing
• Health Economics and Outcomes Research
• Payer Relations/ Evidence
• Regulatory Affairs, Policy
• Public/ Government Affairs
• Payers, HTA Officials and Physicians
• Business Development
• Marketing
• Commercial Executives
• Product Launch
• Commercialization
• Value Strategy
• Product Strategy
• Forecaster
• Finance Officer
• Wearable Sensors
• Electronic &
• Medical Records
• Lab & Biomarkers
• Medical and Pharmacy data
• Technology Science and Development
• Social Media
• Academia
• Pharma and Biotech